Disruptive Insights

  • Home
  • Disruptive Insights

Disruptive Insights With an initial focus on healthcare, Disruptive Insights delivers deeply diligenced research, helping great thinkers make informed decisions.

OUR PRODUCTS


Deep Dives
In-depth (“deep dive”) reports each focused on a particular technology, company, or outside of industry force that has the potential to significantly disrupt the economic prospects of a particular industry or sub-industry. Payer Perspectives
Comprehensive surveys of leading health plans, PBMs, ACOs, integrated networks, and employer coalitions on the current and expected

future coverage dynamics of various therapeutic areas. Payer Hotspots
A quarterly assessment of the most acute areas of focus for leading health plans, PBMs, ACOs, integrated networks, and employer coalitions. WHO WE ARE

The unique confluence of disruptive forces already at play in healthcare will soon enable change at a scale and speed never seen before. Given this backdrop, we believe the “price of entry” for successful leaders will be a nuanced understanding of industry issues and the ability to distill a multitude of variables down to the essential few. We are building a company designed to help healthcare organizations build and maintain this understanding. OUR TEAM
The Disruptive Insights team consists of 2 veteran investment analysts and a staff of junior analysts. Our veteran analysts have 25+ years of combined research experience with a particular focus on industries facing systemic disruptive forces. OUR VISION
To provide clarity and insight in a world of uncertainty


OUR GOAL
To Deliver a highly useful set of products across the spectrum of healthcare, which help enable better decision making

Payer intelligence. How soon before Oncology Rx catches up with cost growth in Specialty? Payers answer here: http://bit...
18/12/2015

Payer intelligence. How soon before Oncology Rx catches up with cost growth in Specialty? Payers answer here: http://bit.ly/1NmmIfe

This Payer Hotspots survey focuses on the potential areas for increased management in specialty and oncology pharmaceuticals. The survey was...

Did you know: There are 81 bills that target Rx pricing in state  ? Rx2016 is right around the corner. http://bit.ly/1P3...
18/12/2015

Did you know: There are 81 bills that target Rx pricing in state ? Rx2016 is right around the corner. http://bit.ly/1P3KeNm

Rx Price Controls: Public, Payer and Political Pushback December 14, 2015/0 Comments/in Uncategorized /by richardTom Horton recently published an...

View heat map of Rx drug price legislation pending a 2016 vote. Will next year be  ? http://bit.ly/1mqiTMd
17/12/2015

View heat map of Rx drug price legislation pending a 2016 vote. Will next year be ? http://bit.ly/1mqiTMd

15/12/2015

In our survey, payers (representing more than 41 million lives) say Oncology will grow as a percent of drug spend by _% in 4 years (weighted average).

You can answer on our Twitter, .

This table shows which states have pending Rx pricing bills, and how many of those bills are awaiting a vote in 2016. Wi...
15/12/2015

This table shows which states have pending Rx pricing bills, and how many of those bills are awaiting a vote in 2016. Will your state pass legislation targeting prescription drug prices in 2016? Read more here: http://bit.ly/1P3KeNm

Disruptive Insights Group You remember just a couple months ago when Turing Pharmaceuticals AG increased the price of th...
03/12/2015

Disruptive Insights Group You remember just a couple months ago when Turing Pharmaceuticals AG increased the price of their therapy for toxoplasmosis by more than 5000%? So do we, and today at Forbes Healthcare Summit, we got a glimpse of how PBMs like Express Scripts feel about Martin Shkreli's (CEO of Turing) strategy when Express Scripts' CMO, Steve Miller stood up to ask Shkreli a question. Read the full transcript of that interaction here at the Disruptive Insights Group Blog: https://disruptiveinsightsgroup.com/value-vs-fiduciary-duty-martin-shkreli-encounters-express-scripts-cmo-steve-miller/

Value vs. Fiduciary Duty: Martin Shkreli encounters Express Scripts CMO, Steve Miller December 3, 2015/0 Comments/in Uncategorized /by richardAt the 2015 Forbes Healthcare Summit, Turing Pharmaceuticals founder, Martin Shkreli answered questions about the ethics of the company’s Daraprim price hike…

13/11/2015

As more and more data rolls in, we're seeing bundled payments grow in Hip & Knee. Now more than ever, it's critical to know how alternative reimbursements are changing cost dynamics in categories like H&K and Spine. Our Payer Insights keep track of how payers are fighting costs in the categories that matter to you! https://lnkd.in/eh2m9TF

Expanding and more representative participation in Medicare’s Bundled Payments for Care Improvement initiative suggests potential for large impact, pending the results of risk-bearing participants.

IT hurdles have surprised some healthcare stakeholders and discouraged others. However, patience will go a long way in f...
11/11/2015

IT hurdles have surprised some healthcare stakeholders and discouraged others. However, patience will go a long way in facing the challenges of on-boarding critical technologies in the post-ACA world. Read more: https://disruptiveinsightsgroup.com/the-virtue-in-value/

Do you have enough good information to make a good decision?New press release from Disruptive Insights is available here...
17/09/2015

Do you have enough good information to make a good decision?

New press release from Disruptive Insights is available here: http://www.prweb.com/releases/2015/09/prweb12966352.htm

Memphis, TN (PRWEB) September 17, 2015 -- After the successful launch of their first report (Will Theranos Turn the Lab Industry Upside Down?) earlier this year, Disruptive Insights Group (Di) is pleased to announce a new web-based healthcare research platform and Payer Insights - the newest additio…

Do you have all the answers in hip and knee? Disruptive Insights is focused on the changing landscape in TJR. This artic...
15/09/2015

Do you have all the answers in hip and knee? Disruptive Insights is focused on the changing landscape in TJR. This article explores the stops, starts and "hold ons" in one of healthcare's most unsustainable interventions.

https://disruptiveinsightsgroup.com/?p=1372

With alternative reimbursements partially mandated in hip and knee (CMS), it’s a good idea to take a look at some of the open questions in TJR.

We are a new web-based research platform taking aim at blind spots in healthcare.Explore our research, articles or downl...
14/09/2015

We are a new web-based research platform taking aim at blind spots in healthcare.

Explore our research, articles or download a free report preview at http://www.DisruptiveInsightsGroup.com.

Help us move the conversation forward! Email us at [email protected]

DI delivers healthcare research designed to help investors and industry executives make informed decisions about new and emerging disruptive forces

Address


Alerts

Be the first to know and let us send you an email when Disruptive Insights posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Disruptive Insights:

Shortcuts

  • Address
  • Telephone
  • Alerts
  • Contact The Business
  • Claim ownership or report listing
  • Want your business to be the top-listed Travel Agency?

Share